secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2026-09-17T12:30:40+00:00
Accession:  0001493152-26-043052
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity Technologies wins Hong Kong patent for CyPath Lung lung cancer diagnostic
--------------------------------------------------------------------------------

- Hong Kong IP Department granted Patent No. HK40048460 covering flow cytometry and fluorescent markers in sputum for lung cancer prediction.
- Patent complements 2025 China patent; strengthens IP in Asia, which accounts for ~1.6M new lung cancer cases annually.
- CyPath Lung clinical trial data: 92% sensitivity, 87% specificity, 88% accuracy, 99% NPV in high-risk patients with nodules <20mm.
- Company holds patents/pending in US, Australia, Canada, China, EU, Japan, Mexico, Singapore.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226043052/0001493152-26-043052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226043052/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-043052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer